# Cardiovascular diseases worsen the maternal prognosis of COVID-19

Carolina Burgarelli Testa <sup>1</sup>, Luciana Graziela de Godoi <sup>2\*</sup>, Maria Rita de Figueiredo Lemos Bortolotto <sup>3</sup>, Nátaly Adriana Jiménez Monroy <sup>4</sup>, Bruna Rodrigues de Mattos <sup>5</sup>, Agatha Sacramento Rodrigues <sup>6</sup> and Rossana Pulcineli Vieira Francisco <sup>7</sup>.

- Division of Obstetrics Clinic, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo/SP, Brazil; carolina.burgarelli@hc.fm.usp.br
- <sup>2</sup> DaSLab (Data Science Lab), Department of Statistics, Federal University of Espírito Santo, Vitória/ES, Brazil; <u>luciana.godoi@ufes.br</u>
- <sup>3</sup> Division of Obstetrics Clinic, Hospital das Clínicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, Brazil; <u>maria.bortolotto@hc.fm.usp.br</u>.
- DaSLab (Data Science Lab), Department of Statistics, Federal University of Espírito Santo, Vitória/ES, Brazil; nataly.monroy@ufes.br
- <sup>5</sup> DaSLab (Data Science Lab), Department of Statistics, Federal University of Espírito Santo, Vitória/ES, Brazil; <u>bruna.mattos@edu.ufes.br</u>
- 6 DaSLab (Data Science Lab), Department of Statistics, Federal University of Espírito Santo, Vitória/ES, Brazil; agatha.rodrigues@ufes.br.
- Discipline of Obstetrics, Department of Obstetrics and Gynecology, Hospital das Clinicas HCFMUSP, Faculty of Medicine, University of São Paulo, São Paulo, São Paulo, Sao Paulo, São Paulo,

Abstract: Cardiovascular diseases are a risk factor for severe cases of COVID-19. There are no studies evaluating whether the presence of CVD in pregnant women and in postpartum women with COVID-19 is associated with a worse prognosis. In an anonymized open database of the Ministry of Health, we selected cases of pregnant and postpartum women who were hospitalized due to COVID-19 infection. Among the 1,876,953 reported cases, 3,562 confirmed cases of pregnant and postpartum women were included, of which 602 had CVD. Patients with CVD had an older age (p<0,001), a higher incidence of diabetes (p<0,001) and obesity (p<0,001), a higher frequency of systemic (p<0,001) and respiratory symptoms (p<0,001). CVD was a risk factor for ICU admission (p<0,001), ventilatory support (p=0.004) and orotracheal intubation in the third trimester (OR 1.30 CI95%1.04-1.62). The group CVD had a higher mortality (18.9% vs. 13.5%, p<0,001), with a 32% higher risk of death (OR 1.32 CI95%1.16-1.50). Moreover, the risk was increased in the second (OR 1.94 CI95%1.43-2.63) and third (OR 1.29 CI95%1.04-1.60) trimesters, as well as puerperium (OR 1.27 IC95%1.03-1.56). Hospitalized obstetric patients with CVD and COVID-19 are more symptomatic. Their management demand more ICU admission and ventilatory support and the mortality is higher.

**Keywords:** Pregnancy; Cardiovascular disease; COVID-19.

#### 1. Introduction

Maternal mortality is one of the most sensitive markers of health care because it has multiple economic and social impacts. Brazil has a maternal mortality rate of 59.1/100,000 live births (1), above the values considered acceptable by the World Health Organization, which established as a millennium goal for Brazil rates below 35/100,000 live births (2).

The presence of cardiovascular diseases (CVD) is among the main indirect causes of maternal mortality in the world, the Mainly in developed countries of which is found in developed countries (3,4). In Brazil, CVD accounted for 7% to 9.6% of maternal deaths in the years 2011 to 2019 (5).

During the COVID-19 pandemic, maternal mortality has increased significantly in the world. Currently, the postpartum period has been recognized as a risk factor for complications such as infection (6). By the time this article was written, Brazil had recorded 13,769 cases of Severe Acute

<sup>\*</sup> Correspondence: Luciana Graziela de Godoi, e-mail <u>luciana.godoi@ufes.br</u>

Respiratory Syndrome (SARS) and 1,461 deaths (12.3%) due to COVID-19 during the postpartum period (7).

Studies reported that CVD is an independent risk factor for severe cases of COVID-19 in the general population. However, there are no studies that have evaluated whether the presence of CVD in pregnant and postpartum women with COVID-19 can be considered a risk factor as well for having a poor prognosis. Furthermore, a study implied that there was an increase in the already high mortality rates in this group of women (8).

#### 2. Materials and Methods

Since the Influenza A (H1N1) pandemic in 2009, the Brazilian Ministry of Health has since established and maintained the Influenza Epidemiological Surveillance Information System (Sistema de Vigilância Epidemiológica de Gripe, SIVEP-Gripe), with the possibility of access to data without the individual identification of the patient (anonymized data), on an open basis (9,10). Thus, according to Brazilian regulations, there is no need for prior approval by institutions board review.

During the COVID-19 pandemic, the notification in the SIVEP-Gripe of cases of patients with SARS hospitalized in all health units in the country has been compulsory. It has enabled the evaluation of diagnosis, demographic and epidemiological data, and the evolution of cases. The case definition of SARS is of an individual with flu-like syndrome with at least two of the following signs and symptoms: fever, chills, sore throat, headache, cough, rhinorrhea, olfactory or taste disorders. They often present with dyspnea/respiratory distress, persistent chest pressure, O2 saturation less than 95% in ambient air, or cyanosis of the lips or face (11).

We conducted a search in the SIVEP-gripe database on May 5, 2021, on the cases reported in the period between the 8th epidemiological week of 2020 (beginning of the pandemics in Brazil) and the 15th epidemiological week of 2021 (period between February 16, 2020, and April 17, 2021).

We selected cases of SARS with a confirmed diagnosis of COVID-19 who had been hospitalized. After that, we selected pregnant and postpartum women aged 10 to 55 years old with data regarding their CVD status.

The evaluated variables were the date of onset of symptoms, age, ethnic group, education, time of pregnancy, risk factors, reported comorbidities (hemopathy, liver disease, asthma, diabetes, neuropathy, pneumopathy, immunodepression, nephropathy and obesity), symptoms, ICU admission, ventilatory support, orotracheal intubation, and outcomes.

The analyses were performed using the statistical software R (12). The qualitative variables are presented as absolute frequency (n) and percentage (%), while the quantitative variables are presented as mean ± standard deviation (SD).

There were two groups according to the presence or absence of CVD. The comparison between the groups for categorical variables was performed through the X2 test. The correction was conducted by Yates and the Fisher's exact test, when necessary. In addition, the odds ratios (OR) were also calculated with the confidence interval being 95% (95% CI). For continuous variables, the comparison between the independent groups was analyzed by the t-Student test or the Wilcoxon signed-rank test with continuity correction, when appropriate. The results were considered statistically significant when p < 0.05.

To control selection biases in non-experimental studies, the CVD and non-CVD groups were balanced with respect to age, ethnic group, obesity, and the presence of diabetes (potential confounding variables in the study). Propensity score matching (PSM) was used for estimating and assessing balancing weights of the observations to make two balanced groups through Inverse Probability of Treatment Weighting Method (IPTW). Logistic regression was the method

used to create the propensity score weights and the Average Treatment Effect (ATE) is estimated for treatment effects based on IPTW. Analyses related to the comparison of symptoms and outcomes in the groups with and without CVD were redone considering the PSM weights. PSM was carried out with the R Weightlt package (13,14). The groups were balanced in relation to age, ethnic group, obesity, diabetes, as can be seen in the article documentation (supplementary material).

#### 3. Results

In the period between the 8th epidemiological week of 2020 and the 15th epidemiological week of 2021 in a consultation held on May 5, 2021, we found 1,876,953 reported cases. We selected only the confirmed and hospitalized cases of COVID-19 in pregnant and postpartum women aged 10 to 55 years who had in their notification the information about the presence or absence of CVD (Figure 1). The final sample size consisted of 3,562 cases, 602 (17%) of which were patients with CVD.

**Figure 1.** Case selection flowchart.

The absolute frequency and percentage growth rate of COVID-19 cases according to the month of the first symptom in the CVD and non-CVD groups are shown in Figure 2.

**Figure 2.** Absolute frequency and percentage of monthly growth rate of COVID-19 cases according to the month of the first symptom in the CVD and non-CVD groups.

We noticed that the absolute numbers were increased in both groups from March to May 2020, with a high level until July. This was when the first wave of the pandemic occurred in Brazil. Furthermore, there was a fall between August and October and a new increase until March 2021, during which the second wave of the pandemic occurred in Brazil. Comparing the growth rates, we noticed that despite presenting similar general trends of growth, in the first wave of the COVID-19 pandemic in Brazil, the group with CVD presented lower growth rates of COVID-19 cases than that of the non-CVD group. This was different from what happened in the 2nd wave in which CVD patients were mostly affected.

The characteristics of the studied population are presented in Table 1. Patients with CVD were older  $(34.76 \pm 8.52 \text{ vs. } 30.00 \pm 7.43 \text{ years}, p < 0,001)$ , more often aged over 35 years (49.8% vs. 28.0%, p < 0,001). When we evaluated the presence of comorbidities, patients with CVD disease had a higher percentage of associated diseases (p < 0,001). Furthermore, the prevalence of diabetes (33.6% vs. 11.4%, p < 0,001), pneumopathy (3.0% vs. 1.1%, p = 0.002), nephropathy (4.4% vs. 1.2%, p < 0,001), and obesity (23.4% vs. 8.8%, p < 0,001) were higher in this group.

**Table 1.** Demographic and clinical characteristics of pregnant and puerperium women hospitalized with COVID-19 confirmed - Brazil, 02/16/2020 to 04/17/2021.

Feature	Presence of Cardiovascular Disease	Absence of Cardiovascular Disease	p

AGE (YEARS)			
Average ± SD	34.76 ± 8.52	$30.00 \pm 7.43$	<0.001
AGE GROUP (YEARS)	N (%)	N (%)	
<20	10 (1.7)	237 (8.0)	<0.001
20-34	292 (48.5)	1895 (64.0)	
≥35	300 (49.8)	828 (28.0)	
ETHNIC GROUP	N (%)	N (%)	
Asian	2 (0.4)	24 (0.9)	0.007
White	214 (42.2)	975 (37.9)	
Indigenous	1 (0.2)	30 (1.2)	
Mixed	244 (48.1)	1375 (53.5)	
Black	46 (9.1)	167 (6.5)	
EDUCATION	N (%)	N (%)	
No schooling	2 (0.7)	11 (0.7)	0.241
1st to 5th grade	33 (12.2)	123 (7.9)	
6th to 9th grade	52 (19.2)	307 (19.7)	
High school	140 (51.7)	857 (55.0)	
College	44 (16.2)	260 (16.7)	
MOMENT OF PREGNANCY	N (%)	N (%)	
1st trimester	34 (5.6)	161 (5.4)	<0.001
2nd trimester	120 (19.9)	471 (15.9)	
3rd trimester	248 (41.2)	1199 (40.5)	
Gestational age ignored	30 (5.0)	84 (2.8)	
Puerperium	170 (28.2)	1045 (35.3)	
RISK FACTORS AND COMORBIDITIES	N (%)	N (%)	
Hemopathy (n=3387)	9 / 437 (2.1)	31 / 2950 (1.1)	0.113
Hepatopathy (n= 3364)	5 / 431 (1.2)	12 / 2933 (0.4)	0.056
Asthma (n= 3369)	40 / 436 (9.2)	199 / 2933 (6.8)	0.087
Diabetes (n= 3417)	158 / 470 (33.6)	337/2947 (11.4)	<0.001
Neuropathy (n=3374)	9 / 431 (2.1)	28 / 2943 (1.0)	0.062
Pneumopathy (n=3373)	13 / 437 (3.0)	31 / 2936 (1.1)	0.002
mmunosuppression (n=3365)	15/433 (3.5)	58 / 2932 (2.0)	0.071

Nephropathy (n=3359)	19/ 433 (4.4)	36 / 2926 (1.2)	<0.001
Obesity (n= 3355)	105 / 449 (23.4)	255 / 2906 (8.8)	<0.001
NUMBER OF COMORBIDITIES (n=3460)	N (%)	N (%)	
0	234 (46.8)	2126 (71.8)	<0.001
1	186 (37.2)	701 (23.7)	
2	64 (12.8)	116 (3.9)	
≥3	16 (3.2)	17 (0.6)	

The evaluation of the presence of symptoms (Table 2) showed that patients with CVD were more frequently symptomatic, with the presence of at least one symptom among those evaluated in 96.3% of cases (96.3% vs. 91.3%, p < 0,001). Systemic symptoms of fever (61.7% vs. 55.8%, p=0.011), cough (75.4% vs. 65.6%, p < 0.01), anosmia (25.8% vs. 18.6%, p = 0.002) and ageusia (26.0% vs. 17.9%, p<0,001) were more prevalent in this group, as were respiratory symptoms.

**Table 2.** Symptoms of COVID-19 in pregnant and puerperal women with cardiovascular disease, hospitalized with confirmed COVID-19 - Brazil, 02/16/2020 to 04/17/2021.

SYMPTOMS	PRESENCE OF	ABSENCE OF			WEIGHTED PROPENSITY SCORE MATCHING	
	CVD	CVD		OR (95% CI)	P	OR (95% CI)
	N (%)	N (%)				
AT LEAST 1 SYMPTOM (n=3537)	574 / 596 (96.3)	2685 / 2941 (91.3)	<0.001	2.49 (1.59 – 3.88)	<0.001	2.28 (1.85 – 2.81)
SYSTEMIC SYMPTOMS						
FEVER (n= 3460)	337 / 546 (61.7)	1625 / 2914 (55.8)	0.011	1.28 (1.06 – 1.54)	0.228	1.06 (0.97 – 1.17)
COUGH (n=3477)	424 / 562 (75.4)	1913 / 2915 (65.6)	< 0.001	1.61 (1.31 – 1.98)	0.138	1.08 (0.98 – 1.19)
SORE THROAT (n=3352)	124 / 491 (25.3)	616 / 2861 (21.5)	0.075	1.23 (0.99 – 1.54)	0.117	1.10 (0.98 – 1.23)
ANOSMIA (n= 2404)	87 / 337 (25.8)	384 / 2067 (18.6)	0.024	1.53 (1.17 – 1.99)	0.002	1.25 (1.08 – 1.43)
AGEUSIA (n=2401)	88/ 338 (26.0)	369 / 2063 (17.9)	<0.001	1.62 (1.24 – 2.11)	< 0.001	1.27 (1.11 – 1.47)
RESPIRATORY SYMPTOMS						
DYSPNEA (n=3469)	401 / 555 (72.3)	1553 / 2914 (53.3)	<0.001	2.28 (1.87 – 2.79)	<0.001	1.64 (1.49 – 1.80)
RESPIRATORY DISTRESS (n=3431)	316 / 529 (59.7)	1361 / 2902 (46.9)	<0.001	1.68 (1.39 – 2.03)	<0.001	1.31 (1.19 – 1.44)
O <sub>2</sub> saturation <95% (n=3408)	301 / 532 (56.6)	1003 / 2876 (34.9)	< 0.001	2.43 (2.02 – 2.94)	< 0.001	1.59 (1.45 – 1.75)
FATIGUE (n= 2411)	104 /342 (30.4)	460 / 2069 (22.2)	0.001	1.53 (1.19 – 1.97)	0.171	1.10 (0.96 – 1.25)
ONE OR MORE RESPIRATORY SYMPTOM (n= 3505)	484 / 578 (83.7)	1992 / 2927 (68.1)	<0.001	2.42 (1.91 – 3.05)	<0.001	1.68 (1.51 – 1.88)
GASTROINTESTINAL SYMP	TOMS					
DIARRHEA (n=3365)	63 / 484 (13)	324 / 2881 (11.2)	0.293	1.18 (0.88 – 1.58)	0.616	0.96 (0.82 – 1.12)

EMESIS (n= 3352)	58 / 481 (12.1)	282 / 2871 (9.8)	0.155	1.26 (0.93 – 1.70)	0.308	1.09 (0.93 – 1.27)
ABDOMINAL PAIN	26 / 227 (11.0)	192 / 2070 / 9 0)	0.250	1 27 (0 07 1 05)	0.226	0.00 (0.72 1.10)
(n= 2387)	36 / 327 (11.0)	183 / 2060 (8.9)	0.250	1.27 (0.87 – 1.85)	0.336	0.90 (0.73 – 1.10)

After applying the Propensity Score Matching (PSM) balancing technique, we found that patients with CVD had an increased risk of dyspnea (OR 1.64 95% CI 1.49-1.80), respiratory distress (OR 1.31 CI 95% 1.19-1.44), and O2 saturation below 95% (OR 1.59 CI95% 1.45-1.75). The presence of at least one respiratory symptom affected 83.7% of this group, while there were only 68.1% without CVD (OR 1.68 95% CI 1.51 – 1.88), as well as the presence of a greater number of associated respiratory symptoms that was more frequent in patients with CVD (p<0.001) (Table 2 and Table 3).

**Table 3.** Respiratory symptoms of COVID-19 in pregnant and postpartum women with cardiovascular disease, hospitalized with confirmed COVID-19 – Brazil, 02/16/2020 to 04/17/2021.

RESPIRATORY SYMPTOMS	PRESENCE OF CARDIOVASCULAR DISEASE	ABSENCE OF CARDIOVASCULAR DISEASE	P	WEIGHTED PROPENSITY SCORE MATCHING
	N (%)	N (%)		P
NO SYMPTOM	94 (16.3)	935 (31.9)	< 0.001	<0.001
1 SYMPTOM	116 (20.1)	640 (21.9)		
2 SYMPTOMS	151 (26.1)	528 (18.0)		
3 SYMPTOMS	164 (27.4)	615 (21.0)		
4 SYMPTOMS	53 (9.2)	209 (7.1)		

The presence of CVD was a risk factor for ICU admission (p < 0,001). After PSM evaluation, we found a 22% higher risk of admission in the CVD group (OR 1.22 95% CI 1.10-1.35), and the risk was increased in the first (OR 1.92 CI95%1.17 -3.15) and second (OR 1.34 IC95%1.05-1.71) trimester and in the puerperium period (OR 1.30 IC95% 1.08-1.55). Similarly, we found that patients with CVD more often required ventilatory support, both noninvasive and invasive (p = 0.004). There was a greater need for orotracheal intubation of CVD patients in the third trimester of pregnancy (OR 1.30 95% CI 1.04-1.62). The length of ICU stay was not statistically different after analysis of the groups via PSM (Table 4).

**Table 4.** Comparison of outcomes in pregnant and postpartum women with cardiovascular disease, hospitalized with confirmed COVID-19 - Brazil, 02/16/2020 to 04/17/2021.

						D PROPENSITY SCORE
OUTCOME	PRESENCE OF	ABSENCE OF	р	OR (95%CI)	MATCHIN	IG
	CVD	CVD			P OR (95%CI)	
ICU admission	N (%)	N (%)				
Total (N=3410)	209 / 565 (37.0)	802 / 2845 (28.2)	< 0.001	1.50 (1.24 – 1.81)	< 0.001	1.22 (1.10 – 1.35)
ICU admission by gestational	N (%)	N (%)				
or postpartum moment	14 (70)	14 (70)				
1st trimester (N= 188)	13 / 31 (41.9)	36 / 157 (22.9)	0.048	2.43 (1.09 – 5.43)	0.014	1.92 (1.17 – 3.15)
2nd trimester (N=571)	47 / 113 (41.6)	143 / 458 (31.2)	0.047	1.57 (1.03 – 2.39)	0.021	1.34 (1.05 – 1.71)
3rd trimester (N=1386)	74 / 233 (31.8)	270 / 1153 (23.4)	0.009	1.52 (1.12 – 2.07)	0.091	1.16 (0.98 – 1.37)

Puerperium (N=1174)	67 / 161 (41.6)	335 / 1013 (33.1)	0.042	1.44 (1.03 – 2.03)	0.005	1.30 (1.08 – 1.55)
Days of ICU stay	Average ± SD	Average ± SD				
Average ± SD	13.46 ± 14.49	10.53 ± 10.73	0.029		0.198	
Ventilatory support	N (%)	N (%)				
No (N=1696)	226 / 555 (40.7)	1470 / 2790 (52.7)				
Non-Invasive (N=1096)	219 / 555 (39.5)	877 / 2790 (31.4)	< 0.001		0.004	
Invasive (N=553)	110 / 555 (19.8)	443 / 2790 (15.9)	10.001		0.001	
Orotracheal intubation for						
gestational or puerperium	N (%)	N (%)				
moment						
1st trimester (N=181)	6/ 29 (20.7)	17 / 152 (11.2)	0.218	2.07 (0.74 – 5.80)	0.078	1.89 (0.98 – 3.62)
2nd trimester (N=550)	23 / 111 (20.7)	66 / 439 (15.0)	0.191	1.48 ( 0.87 – 2.51)	0.252	1.22 (0.89 – 1.67)
3rd trimester (N=1363)	36 / 231 (15.6)	125 / 1132 (11.0)	0.066	1.49 (1.00 – 2.22)	0.023	1.30 (1.04 – 1.62)
Puerperium (N=1159)	39 / 157 (24.8)	224 / 1002 (22.4)	0.556	1.15 (0.78 – 1.70)	0.609	1.06 (0.86 – 1.30)
Total (N= 3345)	110 / 555 (19.8)	443 / 2790 (15.9)	0.026	1.31 (1.04 – 1.65)	0.165	1.10 (0.97 – 1.25)
Outcome - cure x death	N (%)	N (%)				
Cure (N=3047)	488 / 602 (81.1)	2559 / 2960 (86.5)	< 0.001	1.49 (1.19 – 1.88)	< 0.001	1.32 (1.16 – 1.50)
Death (N=515)	114 / 602 (18.9)	401 / 2960 (13.5)	<b>\0.001</b>	1.49 (1.19 – 1.00)	<0.001	1.52 (1.10 – 1.50)
Death by gestational or	N (%)	N (%)				
postpartum moment	14 (70)	14 (70)				
1st trimester (N=195)	4 / 34 (11.8)	15 / 161 (9.3)	0.749	1.30 (0.40 – 4.18)	0.627	1.28 (0.62 – 2.60)
2nd trimester (N=591)	30 / 120 (25.0)	61 / 471 (13.0)	0.002	2.24 (1.37 – 3.67)	< 0.001	1.94 (1.43 – 2.63)
3rd trimester (N=1447)	36 / 248 (14.5)	128 / 1199 (10.7)	0.104	1.42 (0.95 – 2.12)	0.024	1.29 (1.04 – 1.60)
Puerperium (N=1215)	37 / 170 (21.8)	189 / 1045 (18.1)	0.300	1.26 (0.85 – 1.87)	0.031	1.27 (1.03 – 1.56)
Interval between symptom	Average ± SD	Average ± SD				
onset and outcome (days)	Avelage ± 3D	Avelage ± 3D				
Total	$17.10 \pm 12.80$	$16.00 \pm 15.8$	< 0.001		0.912	
Deat	20.04 ± 14.11	20.34 ± 13.86	0.633		0.209	
h	20.04 ± 14.11	20.04 ± 10.00	0.000		0.209	
Cure	$16.39 \pm 12.37$	$15.30 \pm 15.99$	< 0.001		0.723	

Among the patients evaluated, 3,047 had a positive outcome (cure), while 515 died (14.4%). Mortality was higher in the CVD group (18.9% vs. 13.5%, p < 0,001). As shown in Figure 3, the percentage of mortality among patients with CVD was higher in virtually all months evaluated, with an increasing trend in the proportion of deaths since August 2020 and stabilization at higher levels in March and April 2021. After balancing by PSM, the group with CVD presented a 32% higher risk of death (OR 1.32 95%CI 1.16-1.50). The distribution by trimesters of pregnancy and puerperium showed a similar risk of death in the first trimester and increased in the second (OR 1.94 95% CI 1.43-2.63) and third (OR 1.29 CI95% 1.04-1.60) trimesters. The same was found in the puerperium group (OR 1.27 CI95% 1.03-1.56) in patients in the CVD group.

**Figure 3:** Percentage of mortality among patients with CVD, fixed the month of first symptom.

#### 4. Discussion

Patients with CVD presented a higher risk of admission to the ICU, need for ventilatory support in all phases of the pregnancy-puerperal cycle studied and orotracheal intubation in the third trimester. In addition, they had a higher mortality rate in the period analyzed, with a 32% higher risk of death than patients without CVD. The evaluation of moment of pregnancy and puerperium cycle showed an increased risk of death in the second and third trimesters and in the puerperium.

In our population data base, among 3,562 cases of pregnant and puerperal women hospitalized with confirmed COVID-19, we found 602 patients with CVD (17%), a higher incidence than that found in population studies with estimates of around 0.2% to 4% of the pregnant women as carriers of CVD (15,16). It is noted that the frequency of CVD in our study was similar to that referred to us and in the North American population study with 8,207 pregnant women with a positive laboratory test for COVID-19, in which 14% of the pregnant women had CVD (17).

The assessment of declared comorbidities showed that patients with CVD had a greater number of associated comorbidities compared to patients without cardiovascular involvement, with a significantly higher incidence of diabetes and obesity, which were used in the Propensity Score Matching (PSM) balancing technique, as well as age and race, to avoid that these factors could impact the results and the comparison between the groups

Pregnant women with CVD were more symptomatic compared with the control group. They also had more rates of systemic symptoms, such as fever and cough, and respiratory symptoms, such as dyspnea, respiratory distress, and O2 saturation less than 95%. In a systematic review involving 185 obstetric patients evaluated, Narang et al. found 53.2% of patients presented fever, 33.13% cough, and 13% dyspnea (18). In our study, the incidence of symptoms was significantly higher, probably because our cohort included only hospitalized patients. In the CVD group, the prevalence of at least one respiratory symptom was 83.7%, with 72.3% of patients presenting with dyspnea, and 56.6% of patients presenting with a saturation drop below 95%. The presence of significantly higher rates of respiratory symptoms in the group of patients with CVD emphasized the importance of adequate clinical diagnosis of complicated COVID-19 infection. Considering that among the main signs and symptoms of cardiac decompensation during pregnancy are cough and respiratory symptoms such as dyspnea, respiratory distress and saturation loss, symptoms among clinical conditions may overlap. In addition, among the main causes of clinical decompensation of a pregnant woman with a pathological cardiac condition is infection (19–22).

ICU admission occurred in 29.6% of the cases in our cohort. This is a rate higher than that found by Narang et al. in a meta-analysis (3.24%) (18) and by Zambrano et al. in a population study with patients who tested positive for COVID-19 (10.5%) (23). It was observed that when only hospitalized patients were evaluated, the percentage of ICU patients was higher. This was supported by a study by Maeda et al., which involved obstetric patients admitted to a reference hospital for the care of pregnant women with COVID-19 (22.9%) (24). In patients with CVD, admission to the ICU was found in 37% of the cases evaluated. ICU admission indirectly reflected the case with more severe evolution and was directly related to the need for ventilatory support. In our study, patients with CVD required ventilatory support, both noninvasive and invasive, with an orotracheal intubation rate of 19.8%.

In the face of changes imposed by pregnancy, the cardiovascular system undergoes several adaptations that directly impact the management of severe patients and contribute to the higher mortality of these patients (25). Maternal mortality in patients with CVD is high, with significant variations according to their baseline CVD, which ranges from 1 to 5%. However, this population always have a higher mortality compared with the general population (19,26–28). In the context of

the COVID-19 pandemic, the presence of CVD has been recognized as a risk factor for death in several studies and meta-analyses that considered the general population, with incidence of CVD in 37 to 69% of hospitalized cases and lethality rate of 10.5 to 15.5% (29,30). However, there is no study in the literature evaluating mortality in obstetric population with CVD in the presence of COVID-19 infection. In our cohort, mortality among pregnant and puerperal women hospitalized with COVID-19 was 14.4%. In the group of patients with CVD, 18.9% of the patients died. The mortality found was higher than those reported in the literature for the general population, which reinforces our hypothesis that pregnant women have a more severe presentation.

Among the greatest difficulties in assisting patients with CVD, COVID-19 infection is the most common infection that presents with respiratory symptoms, which may be secondary to infection or triggered cardiac decompensation. The high proportion of deaths in this group, sustained throughout the months of the pandemic, demonstrate the difficulty of clinical management especially in those with comorbidities.

In addition, we should consider that the patient with CVD is, in general, a chronic patient. During the pandemic period, in which human and material resources were allocated for the treatment of COVID-19, many patients lost their follow-ups and had treatment delays, which might worsen their primary diseases (31).

Mortality in this group, therefore, results from a potentially severe infection in patients at increased risk due to puerperal pregnancy status and CVD, associated with the risks of decompensation of the primary disease, treatment failure, and difficulty in accessing health.

To date, only one series of five cases has been published evaluating the association between the presence of CVD and pregnancy in the presence of COVID-19 infection (31). We were worth a population database, which allows us to study a large number of hospitalized cases and with the outcome finalized (3,562 cases evaluated and 609 patients with CVD). So far, this is the largest number of obstetric patients with CVD studied in the face of COVID-19 infection. Among the limitations of the study, we should consider that the completion of the notification system included information about the presence or absence of CVD in 39.58% of the notifications, with a high percentage of loss. The difficulty in population-based use was also portrayed by other researchers. In the USA, for instance, only 5.8% (7162) of 122653 cases reported to the CDC had information about health conditions (32). In addition, we found limitation on the type of CV, since the notification form does not allow etiological distinction and interpretation of access to ICU admission in Brazil. This is because only 15% of maternity hospitals in our country have adult ICU beds (33).

#### 5. Conclusions

Obstetric patients with CVD and COVID-19 who are hospitalized are more symptomatic. They require ICU hospitalization and ventilatory support. Moreover, they have higher mortality rate than COVID-19 patients without CVD. Mortality in this group may be a consequence of the association between the severity of COVID-19 infection in pregnant women associated with the presence of CVD (which are, by themselves, are recognized risk factor for ICU admission, orotracheal intubation, and death during pregnancy and puerperium). Further studies are needed in this group of patients to determine the main associated risk factors, analyze individually the etiology of CVD, and thus allow improvements in care and consequent reduction in maternal mortality rates.

### 6. Patents

**Author Contributions:** Conceptualization, C.B.T., L.G.G. and R.P.V.F; Data collect, C.B.T., L.G.G., A.S.R.; Formal analysis, C.B.T., L.G.G., N.A.J.M., B.R.M., A.S.R. and R.P.V.F.; Funding Acquisition: A.S.R. and

R.P.V.F.; Investigation: C.B.T., L.G.G. and R.P.V.F; Methodology, C.B.T., L.G.G., M.R.F.L.B., A.S.R. and R.P.V.F; Supervision, R.P.V.F.; Writing—original draft, C.B.T.; Writing—review & editing, M.R.F.L.B., L.G.G., A.S.R. and R.P.V.F. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Bill & Melinda Gates Foundation, National Council for Scientific and Technological Development (CNPQ - Brasília, Brazil), and Foundation for Research and Innovation Support of the State of Espírito Santo (FAPES - Espírito Santo, Brazil) are funding source.

**Institutional Review Board Statement:** Ethical review and approval were waived for this study due to an open-base study, according to Brazilian regulations.

**Informed Consent Statement:** Patient consent was waived due to it is a populational study in an open anonymized database, according to Brazilian regulations.

**Data Availability Statement:** Datasets are available in the Kaggle public repository at the URL: <a href="https://www.kaggle.com/datasets/agatharodrigues/papermaternal">https://www.kaggle.com/datasets/agatharodrigues/papermaternal</a>. These data were derived from the following resources available in the public domains: <a href="https://opendatasus.saude.gov.br/dataset/bd-srag-2020">https://opendatasus.saude.gov.br/dataset/bd-srag-2021</a>, obtained on May 5, 2021. All the R code and documentation are available in GitHub repository at <a href="https://github.com/observatorioobstetrico/COVID19\_CVD">https://github.com/observatorioobstetrico/COVID19\_CVD</a>.


**Conflicts of Interest:** The authors declare no conflict of interest.

#### References

- 1.Ministério da Saúde, Secretaria de Vigilância em Saúde. Boletim Epidemiológico N° 20. Volume 51. Maio/2020. [Internet]. Volume 51. Maio/2020. 2020 May [cited 2021 Jun 27]. Available from: https://portaldeboaspraticas.iff.fiocruz.br/wp-content/uploads/2020/06/Boletim-epidemiologico-SVS-20-aa.pdf
- 1.Brasil Ministério da Saúde. I Conferência Internacional de Monitoramento dos Objetivos de Desenvolvimento do Milênio no Setor Saúde: Rumo ao Alcance das Metas de 2015 [Internet]. 2010. 131 p. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/conferencia\_internacional\_desenvolvimento\_o bjetivo.pdf
- 2. Saving Mothers' Lives: Reviewing maternal deaths to make motherhood safer: 2006-2008. BJOG An Int J Obstet Gynaecol. 2011 Mar;118:1–203.
- 3.Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32:3147–97.
- 4.Painel de monitoramento de Mortalidade Materna por CID 10 [Internet]. Datasus. 2021 [cited 2021 Jun 26]. Available from: http://svs.aids.gov.br/dantps/centrais-de-conteudos/paineis-de-monitoramento/mortalidade/materna/
- 5. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. Acta Obstet Gynecol Scand. 2020;99(7):823–9.
- 6.Rodrigues, A. and Lacerda, L. and Francisco RPV. Brazilian Obstetric Observatory. arXiv preprint arXiv:2105.06534. 2021.
- 7.Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med [Internet]. 2020 Jun 18 [cited 2021 Jul 30];382(25):e102. Available from: /pmc/articles/PMC7206931/

- 8.Brasil. Ministério da Saúde. Departamento de informática. Open data SUS System [Internet] [Internet]. 2020 [cited 2021 May 5]. Available from: https://opendatasus.saude.gov.br/dataset/bd-srag-2020
- 9.Brasil. Ministério da Saúde. Departamento de. Open data SUS System [Internet] [Internet]. 2021 [cited 2021 May 5]. Available from: https://opendatasus.saude.gov.br/dataset/bd-srag-2021
- 10. Brasil Ministério da Saúde. Definição de caso e notificação [Internet]. Definição de caso e notificação. [cited 2021 May 15]. Available from: https://coronavirus.saude.gov.br/definicao-de-caso-e-notificacao
- 11. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. [Internet]. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. Available from: https://www.r-project.org/
- 12. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=hmbr20
- 13. Greifer N. Package "WeightIt" Type Package Title Weighting for Covariate Balance in Observational Studies [Internet]. 2020 [cited 2021 Jun 27]. Available from: https://ngreifer.github.io/WeightIt/,
- 14. Nanda S, Nelson-Piercy C, Mackillop L. Cardiac disease in pregnancy. Clin Med. 2012 May;12(6):553:560.
- 15. Dobbenga-Rhodes Y a, Privé AM. Assessment and evaluation of the woman with cardiac disease during pregnancy. J Perinat Neonatal Nurs [Internet]. 2006;20(4):295–302. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17310670
- 16. Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status United States, January 22–June 7, 2020. Morb Mortal Wkly Rep [Internet]. 2020 Jun 26 [cited 2021 Jul 25];69(25):769. Available from: /pmc/articles/PMC7316319/
- 17. Narang K, Enninga EAL, Gunaratne MDSK, Ibirogba ER, Trad ATA, Elrefaei A, et al. SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review. Mayo Clin Proc [Internet]. 2020 Aug 1 [cited 2021 Jul 25];95(8):1750. Available from: /pmc/articles/PMC7260486/
- 18. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Vol. 39, Eur Heart J.. 2018. 3165–3241 p.
- 19. Howlett JG, McKelvie RS, Costigan J, Ducharme A, Estrella-Holder E, Ezekowitz J a., et al. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs. Can J Cardiol [Internet]. 2010 Apr [cited 2013 Dec 25];26(4):185–202. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0828282X10703676
- 20. Silversides CK, Grewal J, Mason J, Sermer M, Kiess M, Rychel V, et al. Pregnancy Outcomes in Women With Heart Disease: The CARPREG II Study. J Am Coll Cardiol. 2018;71(21).

- 21. Testa CB, Borges VTM, Bortolotto MRDFL. Pregnancy in patients with heart disease / Cardiopatia e gravidez. Rev Med. 2018; 97(2), 177-186. https://doi.org/10.11606/issn.1679-9836.v97i2p177-186
- 22. Zambrano LD, Ellington S, Strid P, Galang RR, Oduyebo T, Tong VT, et al. Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status — United States, January 22—October 3, 2020. 2020 [cited 2021 Jul 30]; Available from: https://www.cdc.gov/coronavirus/2019ncov/downloads/cases-updates/case-
- 23. Maeda M de FY, Brizot M de L, Gibelli MABC, Ibidi SM, Carvalho WB de, Hoshida MS, et al. Vertical transmission of SARS-CoV2 during pregnancy: A high-risk cohort. Prenat Diagn [Internet]. 2021 Jun 14 [cited 2021 Jul 25]; Available from: /pmc/articles/PMC8242902/
- 24. Ruys TP, Cornette J, Roos-Hesselink JW. Pregnancy and delivery in cardiac disease. J Cardiol. 2013;61(2):107–12.
- 25. Ruys PTE, Hall R, Johnson MR, Webb G, Roos-Hesselink JW. Who Classification As a Risk Predictor in Pregnancy and Heart Disease. J Am Coll Cardiol. 2012;59(13):E843.
- 26. Avila WS, Rossi EG, Ramires JAF, Grinberg M, Bortolotto MRL, Zugaib M, et al. Pregnancy in patients with heart disease: experience with 1,000 cases. Clin Cardiol. 2003 Mar;26(3):135–42.
- 27. Avila WS, Ribeiro VM, Rossi EG, Binotto MA, Bortolotto MR, Testa C, et al. Pregnancy in women with complex congenital heart disease. A constant challenge. Arq Bras Cardiol. 2019;113(6):1062–9.
- 28. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res [Internet]. 2020 Aug 1 [cited 2021 Jul 24];116(10):1666. Available from: /pmc/articles/PMC7197627/
- 29. Izcovich A, Ragusa MA, Tortosa F, Marzio MAL, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review. PLoS One [Internet]. 2020 Nov 1 [cited 2021 Jul 24];15(11). Available from: /pmc/articles/PMC7671522/
- 30. Tilve A, Mahajan NN, Pandey A, Jnanananda B, Gadekar S, Mahale SD, et al. Impact of COVID-19 on pregnant women with Rheumatic heart disease or Peripartum cardiomyopathy. Eur J Obstet Gynecol Reprod Biol [Internet]. 2021 Mar 1 [cited 2021 Jul 24];258:459–61. Available from: https://doi.org/10.1016/j.ejogrb.2021.01.024.
- 31. Team CC-19 R, Team CC-19 R, Team CC-19 R, Chow N, Fleming-Dutra K, Gierke R, et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 United States, February 12–March 28, 2020. Morb Mortal Wkly Rep [Internet]. 2020 Apr 3 [cited 2021 Jul 24];69(13):382. Available from: /pmc/articles/PMC7119513/
- 32. Nakamura-Pereira M, Amorim MMR, Pacagnella R de C, Takemoto MLS, Penso FCC, Rezende-Filho J de, et al. COVID-19 and Maternal Death in Brazil: An Invisible Tragedy. Rev Bras Ginecol e Obs / RBGO Gynecol Obstet [Internet]. 2020 Sep 8 [cited 2021 Jul 25];42(08):445–7. Available from: http://www.thieme-connect.com/products/ejournals/html/10.1055/s-0040-1715138



## Figure 1




Figure 2




Figure 3